600 patients67,035 observations120 daysLIVE

Patient P-01448

Synthetic patientNBL-101 · Day 117 · 55–64 · F · baseline S17Steering view · 3DOpen companion preview
Is the drug working?

Therapy response 85 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 89%, therapy response 94 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: gi toxicity 16, systemic toxicity 14, no drift from the model.

Still taking it?

9 of 9 scheduled doses in the last 60 days are biologically confirmed (100%). Dose signature: resting HR +3 bpm, HRV −8 ms.

last 9 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 124Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
93% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-01448 is on day 117 of NBL-101 (SR, baseline S17): response improving, tolerance favorable, GI deteriorating. Over 14 days response moved +14 and GI +6; discontinuation risk is 18%. The state is in the restoration basin, heading towards restoration.

Butyrate capacity 70/100, diversity 3.7, rapid metabolizer. Pushing it down: Klebsiella pneumoniae 3.956% (LPS load) (-19.3), Alcohol (-17.1), Rapid metabolizer (-13). Pulling it up: Butyrate producers intact (+12.1), Daily walks resumed (+3.3). From the daily log: alcohol +5.1 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Improving
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
18%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (weekly infusion, day 1 of each 7-day cycle)
  1. Day 0 NBL-101 startedBaseline state S17

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • GI instability+6
  • Treatment adherence+6
  • Inflammatory activity+3
  • Toxicity+2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    GI burden
    Companion
    16.4/100
    improving · -2.9 vs previous 14 d
    Toxicity
    Blood
    14.2/100
    stable · +0.1 vs previous 14 d
    Sleep quality
    Wearable
    49.4/100
    improving · +2.4 vs previous 14 d
    Energy level
    Daily log
    6.8/10
    improving · +0.4 vs previous 14 d
    Stress level
    Daily log
    3.3/10
    improving · -0.5 vs previous 14 d
    Steps
    Wearable
    5,338
    stable · -20 vs previous 14 d
    Adherence
    Companion
    92.8 %
    stable · +1.3 vs previous 14 d
    This trajectory is doing well — what to keep, what to watch
    Steering view →

    Heading towards restoration · 100 from the failing basin, 16 from restoration.

    Good elements to keep
    • Butyrate producers intact
      hidden · steering +12.1
    • Daily walks resumed
      perturbation · steering +3.3
    Main detractors to watch
    • Klebsiella pneumoniae 3.956% (LPS load)
      hidden · steering -19.3
    • Alcohol
      perturbation · steering -17.1
    • Rapid metabolizer
      hidden · steering -13
    • Enterobacteriaceae elevated
      hidden · steering -12
    • Alcohol
      detractor · GI +5.1 next day
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Alcohol
      +5.1detractor · 95%
    • Histamine load
      +2.2no signal · 41%
    • Spicy / capsaicin
      -1.2no signal · 24%
    • Dietary fat load
      +0.5no signal · 15%
    • Insoluble fibre
      +0.4no signal · 15%
    • Simple carbohydrates
      -0.1no signal · 15%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    30/100
    vs baseline (day 0)
    +17
    1 improved · 9 worsened
    synthetic signature · consistent with this patient's biology
    • 2 opportunists above range: Klebsiella pneumoniae, Streptococcus gallolyticus
    • 2 keystone species absent
    • 6 resistance genes
    Pathogens / opportunists2/5
    from 1
    Keystone species2/8
    from 1
    Diversity0/2
    Metabolic modules0/4
    Vitamin synthesis2/7
    from 1
    Oral translocation1/1
    from 0
    Host DNA0/1
    Tissue recycling0/1
    Central mechanisms0/2
    Virulence factors2/2
    from 1
    Antibiotic resistance genes6/6
    from 3
    Genetic predisposition2/2
    Opportunists above range
    Klebsiella pneumoniae 3.956% AR
    Streptococcus gallolyticus 1.319% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 3.08 · butyrate 707 CPM · SCFA 1148
    2 vitamins below
    Host & mechanisms
    tissue recycling 35/100
    oral translocation 3.02% AR
    6 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Drug metabolism and exposure 35
      • DNADPYD *2A → slower clearance
    • Butyrate / short-chain fatty acid production 25
      • MicrobiomeF. prausnitzii depleted
    DNA
    Fictional pharmacogenomic panel
    • DPYD *2A heterozygous
      Slower drug clearance
    • CYP2D6 Rapid metabolizer
      Expected exposure
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 3.7 · butyrate capacity 70/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    51 ms
    Sleep
    6.6 h
    Steps
    5,558
    Resting HR
    60 bpm
    Daily log: GI score 16, nutritional resilience 68, adherence 93.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • Keep the current walking rhythm
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0148131%S15AD-05no change67
    P-0146824%S03AD-05no change50
    P-0176449%S15BR-03no change85
    P-0148943%S05BR-03improved83
    P-0176640%S01BR-03improved83
    P-0141137%S13BR-03no change76
    P-0166438%S07CR-01improved85
    P-0189635%S06CR-01improved73
    P-0172525%S01CR-01improved62
    P-0142840%S18DT-01improved82
    P-0147239%S20DT-01no change82
    P-0152834%S20DT-01improved89